Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease
- PMID: 17683792
- DOI: 10.1016/j.brainresbull.2007.05.009
Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease
Abstract
The dopaminergic modulation of prefrontal function in Parkinson's disease (PD) has been consistently demonstrated. There is evidence that the effects of pharmacological manipulations on cognitive performances are described by an "Inverted-U" shaped curve. Neuroimaging studies performed before and after an overnight withdrawal from therapy showed significant differences between drug states, but did not control for the relative impact of the long duration response to levodopa. Here we evaluate the brain response after a complete pharmacological washout by correlating dopaminergic-related changes of this response to changes in performance during cognitive interference. Twelve idiopathic PD patients were studied with functional MRI while performing a modified version of the Stroop task. Patients were scanned twice: (1) following a prolonged washout procedure ("OFF" state) and (2) 90-120 min after the administration of levodopa ("ON" state). Task-related changes of PD patients were compared to those of matched healthy controls. Healthy controls displayed prefrontal and parietal responses that were positively correlated with task accuracy. In the "OFF" state, PD patients showed significant responses in anterior cingulate and pre-supplementary motor area, which are hypothesized to operate at a higher level of basal dopaminergic modulation. Levodopa administration attenuated such responses and enhanced the response of prefrontal cortex (PFC), which was correlated with improved accuracy. Results demonstrate that the behavioral effects of pharmacological manipulations of the dopamine system are highly dependent on the baseline status of PFC. When a true hypodopaminergic state is induced in PD patients, cognitive interference might significantly benefit from the administration of levodopa via an enhanced PFC response.
Similar articles
-
Brain dopaminergic modulation associated with executive function in Parkinson's disease.Mov Disord. 2009 Oct 15;24(13):1962-9. doi: 10.1002/mds.22709. Mov Disord. 2009. PMID: 19672989
-
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.Mov Disord. 2012 Mar;27(3):364-71. doi: 10.1002/mds.24017. Epub 2011 Nov 10. Mov Disord. 2012. PMID: 22076870
-
Changes of functional connectivity of the motor network in the resting state in Parkinson's disease.Neurosci Lett. 2009 Aug 21;460(1):6-10. doi: 10.1016/j.neulet.2009.05.046. Epub 2009 May 20. Neurosci Lett. 2009. PMID: 19463891
-
[Levodopa and cognitive disorders in Parkinson's disease].Rev Neurol. 2006 Jul 16-31;43(2):95-100. Rev Neurol. 2006. PMID: 16838257 Review. Spanish.
-
Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.Neurosci Biobehav Rev. 2006;30(1):1-23. doi: 10.1016/j.neubiorev.2005.03.024. Epub 2005 Jun 1. Neurosci Biobehav Rev. 2006. PMID: 15935475 Review.
Cited by
-
Genetic Influence on Slope Variability in a Childhood Reflexive Attention Task.PLoS One. 2015 Jun 23;10(6):e0130668. doi: 10.1371/journal.pone.0130668. eCollection 2015. PLoS One. 2015. PMID: 26102342 Free PMC article.
-
Altered praxis network underlying limb kinetic apraxia in Parkinson's disease - an fMRI study.Neuroimage Clin. 2017 Jul 18;16:88-97. doi: 10.1016/j.nicl.2017.07.007. eCollection 2017. Neuroimage Clin. 2017. PMID: 28765808 Free PMC article.
-
Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.Ther Adv Psychopharmacol. 2013 Apr;3(2):101-13. doi: 10.1177/2045125312470130. Ther Adv Psychopharmacol. 2013. PMID: 24167681 Free PMC article. Review.
-
The Stroop Color and Word Test.Front Psychol. 2017 Apr 12;8:557. doi: 10.3389/fpsyg.2017.00557. eCollection 2017. Front Psychol. 2017. PMID: 28446889 Free PMC article. Review.
-
Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.NPJ Parkinsons Dis. 2017 Jul 7;3:23. doi: 10.1038/s41531-017-0024-2. eCollection 2017. NPJ Parkinsons Dis. 2017. PMID: 28702504 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous